Current therapies for Herpes Simplex Virus (causing cold sores, fever blisters, and genital herpes) and Varicalla Zoster Virus (causing shingles) infection include the use of antiviral drugs such as acyclovir, famciclovir, penciclovir, and valacyclovir. These drugs act by stalling the synthesis of viral DNA. These drugs are associated with unwanted side effects, with potential to cause viral DNA mutation, leading to drug-resistant viral mutants. The AverTeaX® technology is completely different to these compounds in its anti-viral mechanisms. Dr Hsu’s research has shown that the patent-protected compounds in AverTeaX® formula are able to inhibit HSV viral infection and inactivate the virus.

The clinical study data has been published recently in the Oct issue of journal of Inflammation and Allergy- Drug Targets. The abstract states “These results suggest that this proprietary topical preparation could be used effectively to prevent and treat HSV-induced symptoms, and warrants further clinical investigation”. The paper concludes “Due to the similarities among herpes simplex virus family members and previously reported in vitro data, we hypothesize that EGCG-acyl esters could be effective against genital herpes (HSV-2), shingles (varicella zoster virus), and other viral-induced symptoms as a preventive and therapeutic agent without a known side effect. Another recent paper described the protective effects of the compound against HSV-1 in cell culture experiments (Oliveira et al, Food and Chemical Toxicity, Nov 23, 2012. Epub). This study concludes that the compound “may provide a novel treatment for HSV-1 infections.”